[September 30, 2016]

Primary Progressive Multiple Sclerosis (PPMS) Therapeutics Report 2016 - Pipeline Review Featuring 7 Companies & 11 Molecules - Research and Markets

Research and Markets has announced the addition of the "Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016" report to their offering.

Primary Progressive Multiple Sclerosis (PPMS) pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Our latest report Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Primary Progressive Multiple Sclerosis (PPMS) Primary-progressive multiple sclerosis (PPMS) is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. Symptoms include problems in speech or swallowing, visual problems, fatigue and pain, bladder and bowel difficulties. The molecules developed by Compaies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 2, 1 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.

Key Topics Covered:

1. Introduction
2. Primary Progressive Multiple Sclerosis Overview
3. Therapeutics Development
4. Pipeline Products for Primary Progressive Multiple Sclerosis - Overview
5. Pipeline Products for Primary Progressive Multiple Sclerosis - Comparative Analysis
6. Primary Progressive Multiple Sclerosis - Therapeutics under Development by Companies
7. Primary Progressive Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes
8. Primary Progressive Multiple Sclerosis Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Primary Progressive Multiple Sclerosis - Products under Development by Companies
13. Primary Progressive Multiple Sclerosis - Products under Investigation by Universities/Institutes
14. Primary Progressive Multiple Sclerosis - Companies Involved in Therapeutics Development

• F. Hoffmann-La Roche Ltd.
• Genzyme Corporation
• Glialogix, Inc.
• Kyorin Pharmaceutical Co., Ltd.
• MedDay SA
• Santhera Pharmaceuticals Holding AG
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/mrjckb/primary

View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005619/en/

[ Back To TMCnet.com's Homepage ]